10407results about "Organic chemistry methods" patented technology

A compound having the following structure of Formula (I): or a stereoisomer of the compound, tautomer of the compound, or salt thereof, wherein R1, R2, L, X, Y, A, and B are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

Embodiments of the present invention provide methods and intermediates for the large scale preparation of 2, 4, 6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl] benzamide hemisuccinate, as well as formulations and product forms prepared by these methods. Embodiments of the present invention further provide for the preparation of lamidetan acetate (2, 4, 6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl] benzamide acetate) and / or a pharmaceutical composition thereof, and / or the use of lamidetan acetate and formulations thereof in subcutaneous drug delivery.

The invention relates to a fused heteroaryl compound, a preparation method thereof and application of the fused heteroaryl compound in medicine. Specifically, the invention relates to a fused heteroaryl compound as shown in a general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound and application of the compound as a therapeutic agent, in particular to application of the compound in preparation of drugs for inhibiting KRAS amplification and / or mutant activity. Wherein each group in the general formula (I) is defined in the specification. # imgabs0 #

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

The invention discloses a hydroxytyrosol-ergothioneine eutectic crystal as well as a preparation method and application thereof, and belongs to the technical fields of medicines, foods, daily chemicals and the like. The invention provides a hydroxytyrosol-ergothioneine eutectic crystal. The X-ray powder diffraction pattern of the hydroxytyrosol-ergothioneine eutectic crystal has characteristic diffraction peaks at least corresponding to the positions where the 2 theta value is 4.21 degrees + / -0.2 degrees, 8.36 degrees + / -0.2 degrees, 12.29 degrees + / -0.2 degrees, 15.29 degrees + / -0.2 degrees, 19.40 degrees + / -0.2 degrees, 20.98 degrees + / -0.2 degrees, 23.12 degrees + / -0.2 degrees and 28.73 degrees + / -0.2 degrees. According to the hydroxytyrosol-ergothioneine eutectic, the melting point of hydroxytyrosol is increased, the hygroscopicity of hydroxytyrosol is remarkably reduced, and meanwhile the stability of hydroxytyrosol and ergothioneine is enhanced. In addition, after the ergothioneine hydroxytyrosol forms the eutectic crystal, the ergothioneine hydroxytyrosol can also play better anti-oxidation and anti-aging effects.

The invention provides a pyrimidino heterocyclic compound as well as a pharmaceutical composition and application thereof. The invention provides a pyrimidino heterocyclic compound as shown in a formula I, and a stereoisomer, a tautomer, an atropisomer or a pharmaceutically acceptable salt of the pyrimidino heterocyclic compound. The compound disclosed by the invention has good proliferation inhibition activity on NCI-H358 cells, AsPC-1 cells and Capan-1 cells containing KRAS mutation, and has relatively weak proliferation inhibition activity on PC-9 cells wild in KRAS. # imgabs0 #

Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.

The invention discloses a method for extracting astaxanthin by using a biological enzyme, which comprises the following steps of: decomposing cell walls of haematococcus pluvialis at a certain temperature by using the biological enzyme, releasing astaxanthin from the haematococcus pluvialis, dissolving out the astaxanthin by using a certain solvent, and separating and purifying to obtain powdery astaxanthin. According to the method disclosed by the invention, wall breaking is carried out by combining ultrasound and biological enzyme, and a mixed solvent of ethanol and Tween 80 is adopted, so that the extraction rate of astaxanthin reaches 98.1%, the wall breaking time is shortened, and the efficiency is improved.

The invention discloses a preparation method of a GLP-1R agonist Orforglipron, which comprises the following reaction steps: carrying out four-step reaction on an oxopiperidine compound (1) and (4-fluoro-3, 5-dimethylphenyl) hydrazine (2) to obtain a compound 8, and carrying out seven-step reaction on 5-bromo-indolecarboxylic acid (9) to obtain a compound 17. Then, the compound 8 and a compound 17 are subjected to an acid amine condensation reaction, and Orforglipron (LY3502970) is obtained. The preparation method is relatively low in cost, easy to operate, relatively short in synthetic route and suitable for industrial production and application, and the total yield can reach 32%.

The disclosure provides solid forms of Compound A, as described herein. The disclosure also provides pharmaceutical compositions comprising the disclosed solid forms and methods of using the disclosed solid forms and pharmaceutical compositions (e.g., to treat cancer).

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The present invention addresses the problem of providing a method for producing olefins that can sufficiently remove polyamides from waste plastics. [Solution] The method for producing olefins according to the present invention includes a thermal decomposition step of thermally decomposing a waste plastic raw material containing polyolefins and polyamides to obtain a hydrocarbon stream, a separation step of separating a thermal decomposition product of the polyamides from the hydrocarbon stream that has undergone the thermal decomposition step, and a catalytic cracking step of catalytically cracking the hydrocarbon stream that has undergone the separation step in the presence of a catalyst containing zeolite to obtain olefins.

The invention relates to a sodium channel regulator for inhibiting Nav1.8, and provides a compound as shown in a formula I which can be used as the sodium channel regulator for inhibiting Nav1.8, and an isomer of the compound, or a pharmaceutically acceptable salt of the compound, the invention also provides a pharmaceutical composition containing the compound and the isomer thereof, or the pharmaceutically acceptable salt thereof and a carrier or excipient, and a pharmaceutical application of the pharmaceutical composition as a NaV1.8 inhibitor (such as pain, respiratory diseases, neurological disorders, mental diseases and the like).

The invention discloses a micromolecule NSD3 degradation agent as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a micromolecular NSD3 degradation agent, which has a structure as shown in a formula I or a formula II, has a remarkable inhibition effect on NSD3 protein expression, and has remarkable killing and growth inhibition effects on lung squamous carcinoma cells. The small molecule NSD3 degradation agent provides a new scheme for treatment of lung squamous cell carcinoma, and has a good clinical application prospect. # imgabs0 # imgabs1 #

Provided are organometallic compounds including a ligand LA ofAlso provided are formulations including these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.

The invention discloses an inorganic-organic hybrid compound crystal and a preparation method thereof, and belongs to the technical field of organic-inorganic hybrid materials. The preparation method comprises the following steps: mixing raw materials containing hydroiodic acid, organic cage molecules RCC3 and a lead source with a solvent, and carrying out solvothermal reaction to obtain the inorganic-organic hybrid compound crystal. The chemical formula of the prepared inorganic-organic hybrid compound crystal is ({H18 [C72H108N12] 2 [(Pb10I36)]}. 2I), wherein [C72H108N12] is RCC3 acidified by hydroiodic acid, the crystal has a supramolecular three-dimensional structure assembled by a [Pb5I8] 3-anion cluster unit and a protonated RCC3 molecular cage through electrostatic and hydrogen-bond interaction, and belongs to a monoclinic system, and the space group is P21. The crystal structure is a metal halide-based organic-inorganic hybrid crystal constructed by taking an organic molecular cage as nitrogen-containing cations and lead iodide for the first time.

An advantageous isolated morphic form of trilaciclib which is 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, for example in the form of a dihydrochloride salt or a dihydrochloride, dihydrate.

The invention relates to an amido-substituted aromatic heterocycle inhibitor as well as a preparation method and application thereof. Specifically, the compound disclosed by the invention has a structure as shown in a formula (I), and each group is defined in the specification. The invention further discloses a preparation method of the compound and application of the compound as a KRAS mutation inhibitor. The compound has a very good inhibition effect on KRAS mutation and has better pharmacodynamic and pharmacokinetic performance and lower toxic and side effects. # imgabs0 #

The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

Disclosed herein are activatable inactive sonosensitizer compounds, referred to as locked sonosensitizer compounds, designed with a detachable stimuli-responsive tether acting as a trigger or safety, as these compounds restore their inherent sonosensitization activity upon the detachment of the tether. The invention further encompasses pharmaceutical compositions comprising the same, offering a strategic approach to sonodynamic therapy, whereas the compounds and compositions are formulated to be administered and applied under favorable conditions, enhancing their efficacy in the context of therapeutic applications, since the therapeutic methods presented herein are more versatile and efficient compared to presently known SDT methods due to the controlled activation of the sonosensitizer.